Abstract: An apparatus for rolling strip having a periodically fluctuating strip thickness has a roll stand with a set of rollers defining a gap, an adjustment actuator for adjusting the gap of the set of rollers, unwinder for feeding the strip with an initial thickness to an intake side of the roller gap, winder for receiving the strip with a desired final thickness from an output side of the gap, respective upstream and roller assemblies each having an immersion roller provided upstream of the roll stand between the unwinder and the roll stand and downstream of the roll stand between the roll stand and the winder. The strip is guided around the immersion rollers. A controller sets positions of the immersion rollers while operating the rollers of the roll stand at a constant roller speed, for determining the roller gap in dependence on the setting of the rollers.

Abstract: An apparatus for rolling strip having a periodically fluctuating strip thickness has a roll stand with a set of rollers defining a gap, an adjustment actuator for adjusting the gap of the set of rollers, unwinder for feeding the strip with an initial thickness to an intake side of the roller gap, winder for receiving the strip with a desired final thickness from an output side of the gap, respective upstream and roller assemblies each having an immersion roller provided upstream of the roll stand between the unwinder and the roll stand and downstream of the roll stand between the roll stand and the winder. The strip is guided around the immersion rollers. A controller sets positions of the immersion rollers while operating the rollers of the roll stand at a constant roller speed, for determining the roller gap in dependence on the setting of the rollers.

Abstract: The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.

Abstract: The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.

Abstract: The invention relates to a strain of the yeast Saccharomyces cerevisiae which, owing to deletion of the genomic sequences, no longer synthesizes hexose transporters and, as a consequence, can no longer grow on substrates with hexoses as the only carbon source, and whose ability of growing on a substrate with a hexose as the only carbon source is restored when it expresses a GLUT4 gene.

Abstract: The invention relates to yeast strains in which a human GLUT4 transport or a human GLUT1 transporter can be functionally expressed and to particular GLUT4 transport proteins which can be functionally expressed particularly readily in yeast strains.

Abstract: The present invention relates to a method for identification of a chemical compound which modulates the activity of mammalian GPI-PLC wherein a] a mammalian cell is incubated with glimepiride; b] hcDIGs of the cells of a] are prepared; c] the hcDIGs from b] are incubated with a chemical compound; d] the activity of the GPI-PLC from the hcDIGs of c] is determined.

Abstract: In an embodiment, a fiduciary deposit business object may be used to manage data relating to cash flow instruments. The business object may be structured in an embodiment to include a plurality of tables, including transaction, collateral, activity, cash flow, and/or adjustment tables. In an embodiment, when a settlement activity is recorded in the business object, a financial calculation procedure may be initiated. The financial calculation procedure may use data stored in the tables in a financial calculation, such as a gain/loss calculation, based on the location of the data in a specific table, such as whether the data was recently added. After completing the financial calculation, data in the business object may be updated and/or a result may be sent to an accounting system. Additional data, such as data in the collateral and other tables, may also be sent to the accounting system depending on accounting reporting requirements.

Abstract: Disclosed are compounds of the general formula (I), with the definitions of the substituents R1 to R5, A and X being detailed in the text, and to their physiologically tolerated salts, to processes for preparing these compounds and to the use thereof as inhibitors of hormone-sensitive lipase (HSL).

Abstract: The invention relates to yeast strains in which a human GLUT4 transport or a human GLUT1 transporter can be functionally expressed and to particular GLUT4 transport proteins which can be functionally expressed particularly readily in yeast strains.

Abstract: The invention therefore relates to compounds of the formula I in which the variables are as defined in the specification, to pharmaceutical compositions containing them and to their use for therapeutically lowering blood glucose levels.

Abstract: The invention relates to pyrimido[5,4-e][1,2,4]triazine-5,7-diones, pharmaceutically acceptable salts thereof and physiologically functional derivatives. The invention therefore relates to compounds of the formula I, in which the radicals have the given meanings, and to their physiologically tolerated salts and processes for preparing them. The compounds are suitable for use as antidiabetics, for example.

Abstract: The present invention relates to kinase inhibitor compounds and derivatives thereof as well as compositions comprising them consisting of the structure of formula I: Wherein R1, R2, A, B, D and E are defined herein. These 4-benzimidazol-2-ylpyridazin-3-ones and their derivatives and compositions comprising them are useful in the treatment of neurological disorders such as Alzheimers' disease, Parkinsons' disease, obesity, hypertension and the like. These pyridazinone derivatives particularly inhibit the metabolic activity of glycogen synthase kinase-3 ? (GSK-3?) which is believed to cause the neurodegeneration that results in these diseases.

Abstract: The present invention relates to pyridazinone compounds and their derivatives according to the general formula (I), with the substituents X, R1 and R2 defined herein, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase GSK-3? (glycogen synthase kinase-3?) which are useful in the treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, strokes, cranial and spinal traumas and peripheral neuropathies, obesity, metabolic diseases, type II diabetes, essential hypertension, atherosclerotic cardiovascular diseases, polycystic ovary syndrome and syndrome X or immunodeficiency.

Abstract: The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.

Abstract: The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.

Abstract: The invention relates to yeast strains in which a human GLUT4 transport or a human GLUT1 transporter can be functionally expressed and to particular GLUT4 transport proteins which can be functionally expressed particularly readily in yeast strains.

Abstract: A platform for industrial installations, in particular for high-pressure descalers (3a) or other machines (3) with optionally bundled supply, discharge, and/or distribution conduits (11) which in operational position, are connectable with fixed conduits of a respective machine (3), can be provided as a central installation for connecting media and power lines that can be monitored and easily inspected, with an arrangement being carried out in an immediate proximity with predetermined distance, lateral position and height with regard to a connectable machine (3) with control units (4), devices (4), drives (5) and drive consoles (5a), distribution blocks (6), valve units (7), control elements and the like being distributed over a horizontal, polygonal platform foundation surface (2) according to their functions with regard to the machine (3).

Abstract: The invention refers to a protein from plasma membrane of adipocytes. The protein has specific binding affinity to phosphoinositoylglycans. It regulates glucose uptake by circumventing the insulin signaling cascade.

Abstract: Disclosed are compounds of the general formula (I), with the definitions of the substituents R1 to R5, A and X being detailed in the text, and to their physiologically tolerated salts, to processes for preparing these compounds and to the use thereof as inhibitors of hormone-sensitive lipase (HSL).